|
Balance Sheet Cash Flow Statement 550 Hills Dr., 3rd Fl. Bedminster, NJ 07921 NJ Tel. 908-450-5300 Fax 903-450-5351 |
Type: Public
On the web:
http://www.npsp.com
Employees:
47
Employee growth: 14.6%
NPS Pharmaceuticals' calcium receptor technology is the launching point for its development of treatments for hyperparathyroidism (HPT) and osteoporosis. The company worked with Amgen and the pharmaceutical unit of Kirin Brewery to develop Sensipar, which targets secondary HPT, a disease in which the overproduction of parathyroid hormone causes a calcium imbalance. Amgen sells the drug everywhere but Japan, where Kirin owns the marketing rights. NPS has two other compounds in late-stage clinical trials: osteoporosis drug Preos (already approved in Europe) and recombinant protein Gattex, a potential treatment for gastrointestinal disorders. Swiss firm Nycomed has European marketing rights for both drugs.
Key numbers for fiscal year ending December, 2008:
Sales: $102.3M
One year growth: 18.6%
Net income: ($31.7)M
Officers:
Chairman: Peter G. Tombros
President, CEO, and Director: François Nader
SVP and CFO: Luke M. Beshar
Competitors:
Johnson & Johnson
Merck Serono
Prometheus Labs
